Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
Ross, Kathryn M.
Fulchino, Lisa A.
MetadataShow full item record
CitationKesselheim, Aaron S., Wesley Eddings, Tara Raj, Eric G. Campbell, Jessica M. Franklin, Kathryn M. Ross, Lisa A. Fulchino, Jerry Avorn, and Joshua J. Gagne. 2016. “Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval.” Edited by Christina Chan. PLOS ONE 11 (10) (October 21): e0163339. doi:10.1371/journal.pone.0163339.
AbstractBackground: Generic drugs are cost-effective versions of brand-name drugs approved by the Food and Drug Administration (FDA) following proof of pharmaceutical equivalence and bioequivalence. Generic drugs are widely prescribed by physicians, although there is disagreement over the clinical comparability of generic drugs to brand-name drugs within the physician community. The objective of this survey was to assess physicians' perceptions of generic drugs and the generic drug approval process.
Methods and Findings: A survey was administered to a national sample of primary care internists and specialists between August 2014 and January 2015. In total, 1,152 physicians comprising of internists with no reported specialty certification and those with specialty certification in hematology, infectious diseases, and endocrinology were surveyed. The survey assessed physicians’ perceptions of the FDA’s generic drug approval process, as well as their experiences prescribing six generic drugs approved between 2008 and 2012 using product-specific approval pathways and selected comparator drugs. Among 718 respondents (62% response rate), a majority were comfortable with the FDA’s process in ensuring the safety and effectiveness of generic drugs overall (91%) and with letting the FDA determine which tests were necessary to determine bioequivalence in a particular drug (92%). A minority (13–26%) still reported being uncomfortable prescribing generic drugs approved using product-specific pathways. Overall, few physicians heard reports of concerns about generic versions of the study drugs or their comparators, with no differences between the two groups. Physicians tended to hear about concerns about the safety or effectiveness of generic drugs from patients, pharmacists, and physician colleagues.
Conclusions: Physicians hold largely positive views of the FDA's generic drug approval process even when some questioned the performance of certain generic drugs in comparison to brand-name drugs. Better education about the generic drug approval process and standards may alleviate concerns among the physician community and support the delivery of cost-effective health care.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29107456
- HMS Scholarly Articles